Celcuity Inc Achieves Significant Clinical Trial Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy CELC?
Source: Benzinga
Celcuity Inc's stock rose by 5.19% as it crossed above the 5-day SMA, despite the broader market decline with the Nasdaq-100 down 1.79% and the S&P 500 down 1.08%.
This increase is attributed to the company's recent updates on gedatolisib clinical data, revealing a median progression-free survival (PFS) of 16.6 months in the VIKTORIA-1 trial, significantly outperforming the 1.9 months seen with fulvestrant alone. The positive results highlight the therapy's potential for HR+, HER2- breast cancer patients, suggesting a transformative impact on treatment options.
The implications of this data are substantial, as it not only supports future FDA New Drug Application submissions but also positions Celcuity favorably in the oncology market, potentially attracting more investor interest and enhancing its market valuation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 111.710
Low
94.00
Averages
106.50
High
126.00
Current: 111.710
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apis Capital Increases Stake in Garrett Motion by 2.09 Million Shares
- Stake Increase: Apis Capital Advisors, LLC disclosed in a February 17, 2026 SEC filing that it increased its stake in Garrett Motion by 2,090,000 shares, raising its ownership to 6.77%, with the investment now valued at $38.87 million, reflecting a significant $36.96 million increase, indicating strong confidence in the company.
- Performance Metrics: As of February 17, 2026, Garrett Motion's shares were priced at $20.62, representing a remarkable 125.4% increase over the past year, significantly outperforming the S&P 500 by 115.68 percentage points, showcasing the company's robust performance and market recognition in the automotive parts sector.
- Market Demand: Despite the rise of electric vehicles, the automotive industry remains heavily reliant on internal combustion engines, with stringent fuel economy and emissions regulations sustaining demand for turbochargers; Garrett Motion's products enable automakers to meet these requirements while maintaining performance, ensuring revenue stability.
- Investment Outlook: As hybrid vehicles gain traction, Garrett Motion's profitability will depend on steady global vehicle output and ongoing demand for advanced combustion technology, prompting investors to monitor the duration of this transitional phase and its implications for the company's future performance.
See More
Apis Capital Increases Stake in Garrett Motion
- Stake Increase: Apis Capital Advisors, LLC disclosed an increase of 2,090,000 shares in Garrett Motion in a recent SEC filing dated February 17, 2026, with an estimated trade size of approximately $33.28 million, indicating strong confidence in the company.
- Value Appreciation: At quarter-end, the value of Garrett Motion's stake reached $38.87 million, reflecting a $36.96 million increase from the prior period due to both trading activity and price appreciation, further solidifying its position in the portfolio.
- Asset Management Proportion: Following this transaction, Garrett Motion now constitutes 6.77% of Apis Capital's 13F reportable assets under management, highlighting its significance despite not being among the top five holdings in the fund.
- Strong Market Performance: As of February 17, 2026, Garrett Motion shares were priced at $20.62, representing a 125.4% increase over the past year, significantly outperforming the S&P 500 by 115.68 percentage points, underscoring its competitive edge in the automotive parts industry.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors acquired an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong conviction in the company, especially given its 700% stock price surge over the past year.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, reflecting its significant emphasis on the company within its portfolio and reinforcing Celcuity's position among its top five holdings.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, with a market capitalization of $4.97 billion; despite a net loss of $162.72 million over the past year, the company's market potential continues to attract investor interest.
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA for Priority Review, with a goal date of July 17, 2026; if approved, this could provide significant commercial opportunities in the competitive breast cancer market, further enhancing its stock price and market position.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
Perceptive Advisors Increases Stake in Celcuity
- Share Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4, with an estimated trade value of $16.76 million, indicating strong confidence in the company, especially as its stock has surged 700% over the past year.
- Position Value Growth: The fund's position in Celcuity reached 3,160,200 shares valued at approximately $315.20 million at quarter-end, reflecting a $169.16 million increase, which underscores market recognition of the company's future potential.
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA for Priority Review, with a PDUFA goal date of July 17, 2026; if approved, it will enter a substantial breast cancer market with significant potential.
- Investor Attention: Despite the dramatic 700% increase in Celcuity's stock price, long-term investors should monitor the company's execution capabilities and commercialization readiness to maintain a competitive edge in the future market.
See More
Apis Capital Increases Stake in Garrett Motion by 2.09 Million Shares
- Stake Increase: Apis Capital Advisors, LLC disclosed in a February 17, 2026 SEC filing that it increased its stake in Garrett Motion by 2,090,000 shares, raising its ownership to 6.77%, with the investment now valued at $38.87 million, reflecting a significant $36.96 million increase, indicating strong confidence in the company.
- Performance Metrics: As of February 17, 2026, Garrett Motion's shares were priced at $20.62, representing a remarkable 125.4% increase over the past year, significantly outperforming the S&P 500 by 115.68 percentage points, showcasing the company's robust performance and market recognition in the automotive parts sector.
- Market Demand: Despite the rise of electric vehicles, the automotive industry remains heavily reliant on internal combustion engines, with stringent fuel economy and emissions regulations sustaining demand for turbochargers; Garrett Motion's products enable automakers to meet these requirements while maintaining performance, ensuring revenue stability.
- Investment Outlook: As hybrid vehicles gain traction, Garrett Motion's profitability will depend on steady global vehicle output and ongoing demand for advanced combustion technology, prompting investors to monitor the duration of this transitional phase and its implications for the company's future performance.
See More
Apis Capital Increases Stake in Garrett Motion
- Stake Increase: Apis Capital Advisors, LLC disclosed an increase of 2,090,000 shares in Garrett Motion in a recent SEC filing dated February 17, 2026, with an estimated trade size of approximately $33.28 million, indicating strong confidence in the company.
- Value Appreciation: At quarter-end, the value of Garrett Motion's stake reached $38.87 million, reflecting a $36.96 million increase from the prior period due to both trading activity and price appreciation, further solidifying its position in the portfolio.
- Asset Management Proportion: Following this transaction, Garrett Motion now constitutes 6.77% of Apis Capital's 13F reportable assets under management, highlighting its significance despite not being among the top five holdings in the fund.
- Strong Market Performance: As of February 17, 2026, Garrett Motion shares were priced at $20.62, representing a 125.4% increase over the past year, significantly outperforming the S&P 500 by 115.68 percentage points, underscoring its competitive edge in the automotive parts industry.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors acquired an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong conviction in the company, especially given its 700% stock price surge over the past year.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, reflecting its significant emphasis on the company within its portfolio and reinforcing Celcuity's position among its top five holdings.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, with a market capitalization of $4.97 billion; despite a net loss of $162.72 million over the past year, the company's market potential continues to attract investor interest.
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA for Priority Review, with a goal date of July 17, 2026; if approved, this could provide significant commercial opportunities in the competitive breast cancer market, further enhancing its stock price and market position.
See More
Perceptive Advisors Acquires 431,432 Shares of Praxis Precision Medicines
- Share Acquisition Details: Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares during Q4 2025, with an estimated transaction value of $80.34 million, reflecting strong confidence in the company's future prospects.
- Position Value Growth: Following this acquisition, the value of Praxis's holdings reached $588.30 million, an increase of $505.38 million from the previous quarter-end, indicating significant stock price appreciation and positive investor sentiment.
- Financial Overview: As of February 17, 2026, Praxis shares were priced at $328.04, up 320% year-over-year, despite a net loss of $273.04 million in 2025, suggesting market optimism regarding its future product pipeline.
- R&D and Market Outlook: Praxis has submitted two NDAs to the FDA and is actively preparing for commercialization, with multiple clinical trial results expected in 2026, which could further enhance its market position in the central nervous system sector.
See More
Perceptive Advisors Increases Stake in Celcuity
- Stake Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4 2026, with an estimated transaction value of $16.76 million, indicating strong confidence in the company's future growth potential.
- Ownership Proportion Rise: Following this purchase, Perceptive Advisors' stake in Celcuity increased to 5.62%, highlighting its significance within the investment portfolio and further drawing market attention to Celcuity.
- Market Performance: As of February 17, 2026, Celcuity shares were priced at $107.32, reflecting a staggering 700% increase over the past year, underscoring strong market anticipation for its drug development.
- FDA Review Progress: Celcuity's new drug application for gedatolisib has received Priority Review from the FDA, with a decision expected by July 17, 2026, a critical timeline that could significantly impact its future market performance.
See More
Perceptive Advisors Increases Stake in Celcuity
- Share Increase: Perceptive Advisors purchased an additional 203,881 shares of Celcuity in Q4, with an estimated trade value of $16.76 million, indicating strong confidence in the company, especially as its stock has surged 700% over the past year.
- Position Value Growth: The fund's position in Celcuity reached 3,160,200 shares valued at approximately $315.20 million at quarter-end, reflecting a $169.16 million increase, which underscores market recognition of the company's future potential.
- FDA Review Progress: Celcuity's New Drug Application for gedatolisib has been accepted by the FDA for Priority Review, with a PDUFA goal date of July 17, 2026; if approved, it will enter a substantial breast cancer market with significant potential.
- Investor Attention: Despite the dramatic 700% increase in Celcuity's stock price, long-term investors should monitor the company's execution capabilities and commercialization readiness to maintain a competitive edge in the future market.
See More
